A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Open to people ages 18-51

• Signed and dated written informed consent.
• Clinically stable outpatients who have been diagnosed with schizophrenia (as per Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)).
• Patients, who completed participation in the parent trial.
• Women of childbearing potential must use highly effective methods of birth control.
• Have a study partner who interacts with the patient on a regular basis. Further inclusion criteria apply.

• Participant who developed DSM-5 diagnosis other than Schizophrenia or any condition that would prevent the patient from participating in the extension trial since enrolment into the parent phase III trial.
• Any suicidal behavior and/or suicidal ideation of type 5 based on the Columbia Suicidality Severity Rating Scale (C-SSRS) in parent trial and up to and including Visit 1 of this study.
• Positive urine drug screen ≥ 3 times during the treatment period of parent trial.
• Patients who are currently or wish to participate in another investigational drug trial.
• Any clinically significant finding or condition in the judgment of the investigator that would jeopardize the patient´s safety while participating in the trial or their capability to participate in the trial.

Further exclusion criteria apply.